Glioblastoma Multiforme Market Insight, Epidemiology and Market Forecast -2030

Glioblastoma Multiforme Market Insight, Epidemiology and Market Forecast -2030

“DelveInsight Business Research LLP”
DelveInsight’s ‘Glioblastoma Multiforme (GBM) Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Glioblastoma Multiforme (GBM), historical and forecasted epidemiology as well as the Glioblastoma Multiforme (GBM) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Glioblastoma Multiforme Market

DelveInsight’s ‘Glioblastoma Multiforme (GBM) Market’ report delivers an in-depth understanding of the Glioblastoma Multiforme (GBM), historical and forecasted epidemiology as well as the Glioblastoma Multiforme (GBM) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Glioblastoma Multiforme market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Glioblastoma Multiforme (GBM) market size from 2017 to 2030. The report also covers current Glioblastoma Multiforme (GBM) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Glioblastoma Multiforme (GBM) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of Glioblastoma Multiforme (GBM), Gender-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Type-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Age-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme (GBM) Tumour and Diagnosed Incident Population based on Histologic Classification of Glioblastoma Multiforme (GBM) Tumor in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Key Findings

This section provides glimpse of the Glioblastoma Multiforme (GBM) epidemiology in the 7MM.

  • The total diagnosed incident population of Glioblastoma Multiforme in the 7 major markets was estimated to be 28,259 in 2017. In case of Glioblastoma Multiforme patients in the United States, the diagnosed cases were 14,666 in 2017.
  • The total diagnosed incident cases of Glioblastoma Multiforme patients were found to be maximum in males as compared to females in the 7 MM during the study period of 2017–2030.
  • In the EU5 countries, the diagnosed incident population of Glioblastoma Multiforme was found to be maximum in Germany with 2,876 cases followed by France with 2,683 cases in 2017. While, Spain accounted for the lowest diagnosed incident population of 1,403 in 2017.
  • As per Delvelnsight’s analysis, Japan had 1,899 diagnosed incident cases of Glioblastoma Multiforme in 2017.

 

Glioblastoma Multiforme (GBM) Drug Chapters

The drug chapter segment of the Glioblastoma Multiforme (GBM) report encloses the detailed analysis of Glioblastoma Multiforme (GBM) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Glioblastoma Multiforme (GBM) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Glioblastoma Multiforme Marketed Drugs

Avastin: Genentech

Avastin (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody, which acts as angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). Bevacizumab binds to the vascular endothelial growth factor (VEGF) with its receptor VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. This helps in reducing the activity of VEGF and regressing the vascularization of tumors, which normalizes the tumor vasculature and inhibits the formation of new tumor vasculature, thereby preventing the tumor growth. VEGF is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer. Bevacizumab was the first clinically available angiogenesis inhibitor in the United States. In September 2014, Genentech reclassified the drug under “Specialty drugs,” only to be available through specialty pharmacies (under FDA’s Risk Evaluation and Mitigation Strategy (REMS) program).

 

Avastin is indicated for the treatment of glioblastoma with progressive disease in adult patients following prior therapy as a single agent. The effectiveness of Avastin in glioblastoma is based on an improvement in objective response rate, wherein no data demonstrate any improvement in disease-related symptoms or increased survival with Avastin.

Product details in the report…

 

Temodar/Temodal: Merck

The active pharmaceutical ingredient in Temodar/Temodal, is an imidazotetrazine derivative of the alkylating agent dacarbazine.

 

Temozolomide is used for the treatment of several brain cancer forms, e.g., as a second-line treatment for astrocytoma and as a first-line treatment for glioblastoma. The therapeutic benefit of temozolomide is due to its ability to alkylate/methylate DNA. This alkylation/methylation destroys the DNA and triggers the death of the tumor cells. Temozolomide targets selectively tumoral tissues; it has an anti-neoplastic effect; it has minimum influence on adjacent brain tissues; it has no severe systemic toxicity, and it is eliminated rapidly.

 

Temodar/Temodal was initially commercialized by Merck in the different countries, whereas Baxter Oncology was responsible for the manufacture of Temodar injection. However, due to patent expiry, the market holds the generic version of the drug. Recently, the gel formulation of Temozolomide has also been approved by Double Bond Pharmaceuticals.

Product details in the report…

 

Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Unfortunately, there is no cure for glioblastoma.

 

Glioblastoma treatment is quite challenging as some cells may respond well to certain therapies, while others may not be affected at all. Because of this, the treatment plan for glioblastoma may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by the additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery. Treatment is palliative and may include surgery, radiation therapy and/or chemotherapy. The best treatment options for each person depending on many factors like the size and location of the tumor; the extent to which the tumor has grown into the surrounding normal brain tissues; and the affected person’s age and overall health.

 

In April 2005, the FDA approved a new indication for Temodar capsules (temozolomide) for concurrent use with radiotherapy for the treatment of adults with newly diagnosed GBM and as maintenance therapy after radiotherapy. Inaddition, in December 2017, the FDA granted full approval of bevacizumab (Avastin) for the treatment of adults with recurrent glioblastoma that has progressed following prior therapy. In case of European and Japanese market, only Temodar has been approved by the EMA and MHLW respectively, for the treatment of patients with GBM.

 

Glioblastoma Multiforme pipeline is robust and possesses multiple potential drugs in late and mid-stage developments, which is yet to be launched. The pipeline involves drugs with a varied mechanism of action along with different routes of administration, ranging from oral, intravenous, intratumoral, subcutaneous, etc. It is interesting to note that the emerging market of GBM includes budding gene therapy, i.e., Ofranergene obadenovec (VB-111) by VBL Therapeutics, followed by four vaccine/immunotherapy candidates such as VBI-1901, AV-GBM-1 and ITI-1000 (pp65 DC Vaccine), Tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively.

 

The potential candidates with promising results in late- or phase III stage of clinical development include Ofranergene obadenovec (VB-111; VBL Therapeutics), Trans Sodium Crocetinate (Diffusion Pharmaceuticals), and Regorafenib (Bayer).

 

Key Findings

This section includes a glimpse of the Glioblastoma Multiforme (GBM) 7MM market.

  • The market size of GBM in the seven major markets was estimated to be USD 1,005 Million in 2017.
  • The United States accounts for the largest market size of GBM throughout the study period of 2017–2030, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan, which was estimated to be USD 629 Million in 2017.
  • Among the EU5 countries, Germany had the highest market size with USD 73 Million in 2017, while Spain had the lowest market size with USD 35 Million.
  • Japan accounted for the second highest market size in the 7 MM during the forecast period of 2020–2030, which was estimated to be USD 82 Million in 2017.

 

Request for sample pages @ Glioblastoma Multiforme Market 

Table of contents

1. Key Insights

2. Glioblastoma Multiforme Market Overview at a Glance

2.1. Market Share (%) Distribution of GBM in 2017

2.2. Market Share (%) Distribution of GBM in 2030

3. Executive Summary of Glioblastoma Multiforme (GBM)

4. Disease Background and Overview: Glioblastoma Multiforme (GBM)

4.1. Introduction

4.2. Classification of Glioblastoma Multiforme

4.3. Glioblastoma Types

4.3.1. Astrocytomas

4.3.2. Ependymomas

4.3.3. Oligodendrogliomas

4.3.4. Mixed gliomas

4.3.5. Optic pathway gliomas

4.4. Symptoms

4.5. Pathophysiology

4.5.1. Macroscopic and Histological Features of GBM

4.5.2. Genetic and Molecular Pathogenesis

4.6. Inheritance of Glioblastoma Multiforme

4.6.1. Genetic Variations of Glioblastoma Multiforme

4.7. Molecular Classification

4.7.1. Specific Molecular Biomarkers

4.8. Diagnosis of Glioblastoma Multiforme

4.8.1. Neurological Exams

4.8.2. Angiograms

4.8.3. Magnetic resonance imaging (MRI) and computerized Tomography (CT)

4.8.4. Perfusion MRI

4.8.5. MR spectroscopy

4.8.6. Histological Diagnosis

4.8.7. Surgical Biopsy

4.9. Glioblastoma in Nut Shell

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. 7MM Total Diagnosed Incident Patient Population of Glioblastoma Multiforme

6. Country Wise-Epidemiology of Glioblastoma Multiforme

6.1. United States

6.1.1. Assumptions and Rationale

6.1.2. Total Diagnosed Incident Population of Glioblastoma Multiforme in the United States

6.1.3. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States

6.1.4. Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States

6.1.5. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States

6.1.6. Diagnosed Incident Population based on Primary Site of GBM in the United States

6.1.7. Diagnosed Incident Population based on Histologic Classification of GBM Tumor in the United States

6.2. EU5 Countries

6.2.1. Assumptions and Rationale

6.3. Germany

6.3.1. Total Diagnosed Incident Population of Glioblastoma Multiforme in Germany

6.3.2. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany

6.3.3. Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany

6.3.4. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany

6.3.5. Diagnosed Incident Population based on Primary Site of GBM in Germany

6.3.6. Diagnosed Incident Population based on Histologic Classification of GBM in Germany

6.4. France

6.4.1. Total Diagnosed Incident Population of Glioblastoma Multiforme in France

6.4.2. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in France

6.4.3. Type-specific Diagnosed Incidence of Glioblastoma Multiforme in France

6.4.4. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in France

6.4.5. Diagnosed Incident Population based on Primary Site of GBM in France

6.4.6. Diagnosed Incident Population based on Histologic Classification of GBM in France

6.5. Italy

6.5.1. Total Diagnosed Incident Population of Glioblastoma Multiforme in Italy

6.5.2. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy

6.5.3. Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy

6.5.4. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy

6.5.5. Diagnosed Incident Population based on Primary Site of GBM in Italy

6.5.6. Diagnosed Incident Population based on Histologic Classification of GBM in Italy

6.6. Spain

6.6.1. Total Diagnosed Incident Population of Glioblastoma Multiforme in Spain

6.6.2. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain

6.6.3 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain

6.6.4. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain

6.6.5. Diagnosed Incident Population based on Primary Site of GBM in Spain

6.6.6. Diagnosed Incident Population based on Histologic Classification of GBM in Spain

6.7. United Kingdom

6.7.1. Total Diagnosed Incident Population of Glioblastoma Multiforme in the United Kingdom

6.7.2. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom

6.7.3. Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom

6.7.4. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom

6.7.5. Diagnosed Incident Population based on Primary Site of GBM in the United Kingdom

6.7.6. Diagnosed Incident Population based on Histologic Classification of GBM in the United Kingdom

6.8. Japan

6.8.1. Assumptions and Rationale

6.8.2. Total Diagnosed Incident Population of Glioblastoma Multiforme in Japan

6.8.3. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan

6.8.4. Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan

6.8.5. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan

6.8.6. Diagnosed Incident Population based on Primary Site of GBM in Japan

6.8.7. Diagnosed Incident Population based on Histologic Classification of GBM in Japan

7. Treatment

7.1. Surgery

7.2. Chemotherapy

7.3. Radiation

7.4. Others

7.4.1. Targeted therapy

7.4.2. Tumor treatment fields (TTF)

7.4.3. Immunotherapy

7.5 Management of Symptoms with Medication

8. Treatment Algorithm

9. The American Society of Clinical Oncology (ASCO) Endorsed American Society for Radiation Oncology (ASTRO) Guideline on Radiation Therapy for Glioblastoma

10. The National Comprehensive Cancer Network (NCCN) Guidelines for Glioblastoma

11. Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions

11.1. Medical Management and Supportive Care

11.2. Standard Therapy

11.3. Surgical Management

11.4. Radiotherapy Considerations

11.5. Recurrent Glioblastoma Scenario

12. SEOM (Medical Oncology Spanish Society) Clinical Guidelines for Diagnosis and Treatment of Glioblastoma

13. Recognized Establishments

14. Unmet Needs

15. Marketed Drugs

15.1. Avastin: Genentech

15.1.1. Drug Description

15.1.2. Regulatory Milestones

15.1.3. Other Development Activities

15.1.4. Safety and Efficacy

15.1.5. Product Profile

15.2. Temodar/Temodal: Merck

15.2.1. Drug Description

15.2.2. Regulatory Milestones

15.2.3. Other Development Activities

15.2.4. Safety and Efficacy

15.2.5. Product Profile

16. Emerging Drugs

16.1. Key Cross Competition

16.2. Other emerging therapies in development

16.3. Ofranergene obadenovec (VB-111): VBL Therapeutics

16.3.1. Product Description

16.3.2. Clinical Development

16.3.3. Safety and Efficacy

16.4. Trans Sodium Crocetinate: Diffusion Pharmaceuticals

16.4.1. Product Description

16.4.2. Clinical Development

16.4.3. Safety and Efficacy

16.5. Regorafenib: Bayer

16.5.1. Product Description

16.5.2. Clinical Development

16.5.3. Safety and Efficacy

16.6. Durvalumab (MEDI4736): MedImmune

16.6.1. Product Description

16.6.2. Clinical Development

16.6.3. Safety and Efficacy

16.7. Tasadenoturev (DNX-2401): DNAtrix

16.7.1. Product Description

16.7.2. Clinical Development

16.7.3. Safety and Efficacy

16.8. ONC201: Oncoceutics

16.8.1. Product Description

16.8.2. Clinical Development

16.8.3. Safety and Efficacy

16.9. Selinexor (KPT-330): Karyopharm Therapeutics

16.9.1. Product Description

16.9.2. Clinical Development

16.9.3. Safety and Efficacy

16.10. VBI-1901: VBI Vaccines

16.10.1. Product Description

16.10.2. Clinical Development

16.10.3. Safety and Efficacy

16.11. Paxalisib (GDC-0084): Kazia Therapeutics

16.11.1. Product Description

16.11.2. Clinical Development

16.11.3. Safety and Efficacy

16.12. AV-GBM-1: Aivita Biomedical

16.12.1. Product Description

16.12.2. Clinical Development

16.12.3. Safety and Efficacy

16.13. MDNA55: Medicenna Therapeutics

16.13.1. Product Description

16.13.2. Clinical Development

16.13.3. Safety and Efficacy

16.14. VAL-083 (Dianhydrogalactitol): DelMar Pharmaceuticals

16.14.1. Product Description

16.14.2. Clinical Development

16.14.3. Safety and Efficacy

16.15. ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics

16.15.1. Product Description

16.15.2. Clinical Development

16.15.3. Safety and Efficacy

16.16. INO-5401+ INO-9012+ Cemiplimab (REGN2810): Inovio Pharmaceuticals

16.16.1. Product Description

16.16.2. Clinical Development

16.16.3. Safety and Efficacy

17. Glioblastoma Multiforme: 7 Major Market Analysis

17.1. Key Findings

17.2. Total Market Size of Glioblastoma Multiforme in the 7 MM

17.3. The United States Market Outlook

17.4. United States Market Size

17.4.1. Total Market size of Glioblastoma Multiforme in the United States

17.4.2. Market Size of Glioblastoma Multiforme by Current Therapies

17.4.3. Market Size of Glioblastoma Multiforme by Emerging Therapies

17.5. EU-5 Countries: Market Outlook

17.6. Germany

17.6.1. Total Market size of Glioblastoma Multiforme in Germany

17.6.2. Market Size of Glioblastoma Multiforme by Current Therapies

17.6.3. Market Size of Glioblastoma Multiforme by Emerging Therapies

17.7. France

17.7.1. Total Market Size of Glioblastoma Multiforme in France

17.7.2. Market Size of Glioblastoma Multiforme by Current Therapies

17.7.3. Market Size of Glioblastoma Multiforme by Emerging Therapies

17.8. Italy

17.8.1. Total Market Size of Glioblastoma Multiforme in Italy

17.8.2. Market Size of Glioblastoma Multiforme by Current Therapies

17.8.3. Market Size of Glioblastoma Multiforme by Emerging Therapies

17.9. Spain

17.9.1. Total Market Size of Glioblastoma Multiforme in Spain

17.9.2. Market Size of Glioblastoma Multiforme by Current Therapies

17.9.3. Market Size of Glioblastoma Multiforme by Emerging Therapies

17.1. United Kingdom

17.10.1. Total Market Size of Glioblastoma Multiforme in the United Kingdom

17.10.2. Market Size of Glioblastoma Multiforme by Current Therapies

17.10.3. Market Size of Glioblastoma Multiforme by Emerging Therapies

17.11. Japan: Market Outlook

17.11.1. Total Market Size of Glioblastoma Multiforme in Japan

17.11.2. Market Size of Glioblastoma Multiforme by Current Therapies

17.11.3. Market Size of Glioblastoma Multiforme by Emerging Therapies

18. Market Access and Reimbursement

18.1. United States

18.2. Europe

18.3. Japan

19. Case Reports

19.1. Glioblastoma and intracranial aneurysms: Case report and review of the literature (United States)

19.2. A New Method for Ethical and Efficient Evidence Generation for Off-label Medication Use in Oncology (A Case Study in Glioblastoma) (United Kingdom)

19.3. Diagnosis and treatment of early-stage glioblastoma (Japan)

20. KOL Reviews

21. Market Drivers

22. Market Barriers

23. SWOT Analysis

24. Appendix

24.1. Bibliography

24.2. Report Methodology

25. DelveInsight Capabilities

26. Disclaimer

27. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/